0 52

Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma

Authors
 Hye Ryun Kim  ;  Chang Geol Lee  ;  Eun Chang Choi  ;  Joo Hang Kim  ;  Yoon Woo Koh  ;  Byoung Chul Cho 
Citation
 Head & Neck, Vol.38(Suppl. 1) : 1653-1659, 2016 
Journal Title
 Head & Neck 
ISSN
 1043-3074 
Issue Date
2016
MeSH
Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols ; Carcinoma, Squamous Cell ; Chemoradiotherapy* ; Cisplatin/administration & dosage* ; Drug Combinations ; Female ; Fluorouracil ; Head and Neck Neoplasms/therapy* ; Humans ; Induction Chemotherapy* ; Male ; Middle Aged ; Oxonic Acid/administration & dosage* ; Taxoids/administration & dosage* ; Tegafur/administration & dosage* ; Young Adult
Keywords
S-1 ; docetaxel ; head and neck ; induction chemotherapy ; squamous cell carcinoma
Abstract
BACKGROUND: The purpose of this study was to assess the efficacy and safety of induction chemotherapy with docetaxel-S-1, and radiotherapy (RT) with concurrent daily cisplatin in locally advanced head and neck carcinoma. METHOD: Fifty patients received 2 cycles of induction chemotherapy with induction chemotherapy with docetaxel and S-1, followed by 7 cycles of RT with concurrent daily cisplatin. RESULTS: The most frequent grade 3 to 4 hematologic toxicity was neutropenia (14%). Forty of 50 patients who completed induction chemotherapy with docetaxel and S-1 subsequently started RT with concurrent daily cisplatin, all within 3 to 4 weeks after the start of the second cycle of induction chemotherapy with docetaxel and S-1. The best response to induction chemotherapy with docetaxel and S-1 and after completion of RT with concurrent daily cisplatin was partial response (PR) in 52.5% and complete response in 47.5%, respectively. With a median follow-up of 61 months, 5-year progression-free survival (PFS) and overall survival (OS) were 63.3% and 65.7%, respectively. CONCLUSION: Administration of induction chemotherapy with docetaxel and S-1 before RT with concurrent daily cisplatin chemoradiotherapy (CRT) resulted in a high response rate with good tolerability, and did not compromise subsequent CRT.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/152473
Full Text
http://onlinelibrary.wiley.com/doi/10.1002/hed.24294/abstract
DOI
10.1002/hed.24294
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Otorhinolaryngology (이비인후과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실)
Yonsei Authors
고윤우(Kho, Yoon Woo)
김주항(Kim, Joo Hang)
김혜련(Kim, Hye Ryun)
이창걸(Lee, Chang Geol)
조병철(Cho, Byoung Chul)
최은창(Choi, Eun Chang)
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse